Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study

References

• Besarab A, Levin A. Defining a renal anemia management period. Am J Kidney Dis. 2000;36:S13–S23.
   PubMed Web of Science ®Google Scholar
• Deicher R, Horl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest. 2006;36:301–309.
   PubMed Web of Science ®Google Scholar
• Zaritsky J, Young B, Wang HJ, et al. Hepcidin—a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051–1056.
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425–4433.
   PubMed Web of Science ®Google Scholar
• Swinkels DW, Wetzels JFM. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2008;23:2450–2453.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T, Geffen D. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122:78–86.
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 2007;18:2569–1578.
   PubMed Web of Science ®Google Scholar
• Ramey G, Deschemin J-C, Durel B, et al. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010;95:501–504.
   PubMed Web of Science ®Google Scholar
• Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976–981.
   PubMed Web of Science ®Google Scholar
• Małyszko J, Małyszko JS, Hryszko T, et al. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol. 2005;25:586–590.
   PubMed Web of Science ®Google Scholar
• Taes YEC, Wuyts B, Boelaert JR, et al. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med. 2004;42:387–389.
   PubMed Web of Science ®Google Scholar
• Prowle JR, Westerman M, Bellomo R. Urinary hepcidin: an inverse biomarker of acute kidney injury after cardiopulmonary bypass? Curr Opin Crit Care. 2010;16:540–544.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ding XQ, Zou JZ, et al. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res. 2011;39:1961–1967.
   PubMed Web of Science ®Google Scholar
• Ibrahim IA, Mohamad UM, Rashad AM, et al. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. Egypt J Intern Med. 2014;26:6–14.
   Google Scholar
• Lin L, Nemeth E, Goodnough JB, et al. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008;40:122–131.
   PubMed Web of Science ®Google Scholar
• Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008;111:924–931.
   PubMed Web of Science ®Google Scholar
• Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol. 2005;100:1185–1194.
   PubMed Web of Science ®Google Scholar
• Lin L, Valore EV, Nemeth E, et al. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 2007;110:2182–2189.
   PubMed Web of Science ®Google Scholar
• Tsouchnikas I, Dounousi E, Papakonstantinou S, et al. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. Nephrology (Carlton). 2009;14:560–564.
   PubMed Web of Science ®Google Scholar
• Chiang CK, Yang SY, Peng YS, et al. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammatory effects. Am J Nephrol. 2009;29:392–397.
   PubMed Web of Science ®Google Scholar
• Arabul M, Gullulu M, Yilmaz Y, et al. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage kidney disease. Clin Biochem. 2008;41:1055–1058.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454.
   PubMed Web of Science ®Google Scholar
• Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997;181:257–266.
   PubMed Web of Science ®Google Scholar
• Gael N, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037–1044.
   PubMed Web of Science ®Google Scholar
• Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99:3505–3516.
   PubMed Web of Science ®Google Scholar
• van der Weerd NC, Grooteman MPC, Bots ML, et al. Hepcidin-25 in chronic hemodialysis patients in related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One. 2012;7:e39783.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461–2463.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effect of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181–2192.
   PubMed Web of Science ®Google Scholar
• Sawara Y, Takei T, Uchida K, et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern Med. 2008;47:1505–1510.
   PubMed Web of Science ®Google Scholar
• Verma A, Ranganna K, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005;96:1290–1292.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:S231–S235.
   PubMed Web of Science ®Google Scholar
• Panichi V, Paoletti S, Mantuano E. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006;21:337–344.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41:S1–S91.
   PubMed Web of Science ®Google Scholar
• Sanguankeo A, Upala S, Cheungpasitporn W, et al. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS One. 2015;10:e0132970.
   PubMed Web of Science ®Google Scholar
• Vaya A, Alis R, Hemandez JL, et al. RDW in patients with systemic lupus erythematosus. Influence of anemia and inflammatory markers. Clin Hemorheol Microcirc. 2013;54:333–339.
   PubMed Web of Science ®Google Scholar
• Hu ZD, Chen Y, Zhang L, et al. Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus. Clin Chim Acta. 2013;425:202–205.
   PubMed Web of Science ®Google Scholar
• Song CS, Park DI, Yoon MY, et al. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. Dig Dis Sci. 2012;57:1033–1038.
   PubMed Web of Science ®Google Scholar
• Cakal B, Akoz AG, Ustundag Y, et al. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci. 2009;54:842–847.
   PubMed Web of Science ®Google Scholar
• Lippi G, Sanchis-Gomar F, Danese E, et al. Association of red blood cell distribution width with plasma lipids in a general population of unselected outpatients. Pol J Cardiol. 2013;7:931–936.
   Google Scholar
• Kucera M, Oravec E, Hirnerova E, et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Angiology. 2014;65:794–799.
   PubMed Web of Science ®Google Scholar
• Akin F, Ayca B, Kose N, et al. Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. Angiology. 2013;64:621–625.
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148:635–640.
   PubMed Web of Science ®Google Scholar